Vertex Pharmaceuticals (VRTX) Q4 2024 earnings summary

Executive summary

• Achieved double-digit revenue growth for the tenth consecutive year, with Q4 2024 revenue of $2.91B (+16% YoY) and full-year revenue of $11.02B (+12% YoY), driven by CF franchise expansion and new product launches.

• Launched new products Alyftrek (CF) and Jurnavics/JOURNAVX (acute pain), both receiving U.S. FDA approvals and expanding the commercial portfolio.

• Casgevy rollout accelerated with over 50 authorized treatment centers globally and initial patient infusions in the U.S. and Middle East.

• Announced leadership transitions: COO Stuart Arbuckle retiring July 2025; CFO Charlie Wagner to assume COO role; Duncan McKechnie promoted to CCO.

• Advanced clinical pipeline with four pivotal trials ongoing and key milestones anticipated in 2025 for zimislecel, povetacicept, and inaxaplin.

Financial highlights

• Q4 2024 product revenue: $2.91B (+16% YoY); full-year 2024 revenue: $11.02B (+12% YoY).

• Q4 non-GAAP operating income: $1.2B; full-year non-GAAP operating income: $4.19B; non-GAAP net income: $1.04B.

• Q4 non-GAAP EPS: $3.98; full-year non-GAAP EPS: $0.42 (impacted by $4.4B Alpine IP R&D charge); diluted GAAP EPS: $(2.08).

• Ended Q4 with $11.2B in cash and investments; $1.2B deployed for share repurchases in 2024.

• Casgevy contributed $10M in FY 2024 revenue.

Outlook and guidance

• 2025 revenue guidance: $11.75–$12B (+8% at midpoint), driven by U.S. growth, Alyftrek launch, and ramping Casgevy and Jurnavics/JOURNAVX.

• 2025 combined non-GAAP R&D, acquired IP R&D, and SG&A expense guidance: $4.9–$5B; GAAP: $5.55–$5.7B.

• 2025 non-GAAP effective tax rate expected at 20.5%–21.5%.

• Multiple catalysts anticipated in 2025, including regulatory approvals, clinical trial data, and global launches.

• Ex-U.S. CF revenue growth to be impacted by IP violation in Russia, most pronounced in Q1.